# QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C)

> **NCT07441317** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 780 (estimated)

## Conditions studied

- Primary Hypercholesterolemia or Mixed Hyperlipidemia

## Interventions

- **DRUG:** QLC7401
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07441317
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2027-12
- **Final completion:** 2028-03
- **Target enrollment:** 780 (ESTIMATED)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07441317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07441317, "QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07441317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*